Jefferies downgrades Nutrien stock rating on demand, supply risks

Jefferies downgraded Nutrien to Hold from Buy and cut its price target to $63 from $96, noting unfavorable 2027–2029 scenarios; the stock last traded around $68.33. The firm lowered 2026 EBITDA by 5%, 2027 by 11%, and 2028 by 26% (2028 EBITDA ~25% below consensus). Offsetting items include Nutrien’s $1.0B senior notes pricing ($500M at 4.850% due 2031 and $500M at 5.350% due 2036) and a White House suspension of certain phosphate fertilizer duties from Morocco for up to eight months.

Analysis

NTR is a terminal-earnings story, not a quarterly-beat story. The market is starting to price that farmer economics can stay weak long enough to matter for 2027-2029 volumes, which means even stable headline fertilizer pricing can still produce lower EBITDA through mix and utilization. The debt issuance helps liquidity and dividend optics, but it does not solve the core issue: if potash supply stays loose and crop margins stay thin, every rally becomes a better exit point for long-only holders. Secondary pressure should show up in MOS/CF and fertilizer-adjacent distributors if import supply relief persists and pricing discipline weakens.

TSM looks like the opposite setup: a strong operating print with a softer share reaction usually means the market is worrying about the next leg of AI capex rather than the current one. That’s often where the upside lives, because raised guidance plus record profitability supports the idea that advanced-node and packaging capacity remain constrained, which should keep pricing and utilization favorable for multiple quarters. The beneficiaries are the foundry supply chain names with real leverage to wafer starts and advanced packaging capex, especially AMAT, LRCX, KLAC, and ASML.

The contrarian miss is that NTR downside may be less about today’s pricing and more about 2028 earnings power rolling over; if that slope is right, the stock can stay cheap for months. Conversely, TSM’s post-print dip may be overdone if investors are using valuation alone to ignore a still-tight capacity cycle. What would reverse the NTR thesis is a meaningful crop-price recovery or another fertilizer pricing leg up; what would break the TSM thesis is any sign of AI-capex normalization or a cut to 2H guidance.

Key Decisions for Investors

• Short NTR on strength or via a 3-6 month put spread; target a move back toward the low-$60s, with the thesis invalidated if 2026 EBITDA guidance turns up or potash pricing re-accelerates.
• Buy TSM on post-earnings weakness for a 6-12 month horizon, or use a call spread if implied vol is elevated; risk is a capex pause or Taiwan geopolitics, but the reward is continued AI-driven multiple support and earnings compounding.
• Watch MOS and CF as the cleaner second-order short if the Morocco phosphate duty suspension is extended or if U.S. phosphate import relief keeps domestic pricing capped; this is a 1-3 month catalyst, not a same-day trade.
• Cover any NTR short if crop prices recover meaningfully or if the market starts repricing 2026-2027 farmer margins upward; that would likely be the first sign the 2028 EBITDA reset has gone too far.